MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
MAIA Biotechnology, Inc. (MAIA), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on October 14, 2025, regarding events occurring on October 13, 2025. The company is headquartered in Chicago, Illinois, and its common stock trades on the NYSE American under the symbol "MAIA".
Key Financial Metrics and Transaction Details
This filing reports a private placement transaction rather than periodic financial results. Key metrics related to the transaction include:
- Securities Issued: 603,769 shares of Common Stock and warrants to purchase an equal number of shares.
- Purchase Price: $1.22 per share.
- Aggregate Gross Proceeds: Approximately $736,600.
- Warrant Terms: Exercise price of $1.52 per share; exercisable after six months; three-year term.
- Use of Proceeds: Funding the starting cost for Step 1 of Part C of the Phase II trial THIO-101 and general working capital.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q for these figures.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement with accredited investors. This transaction increases the company's share count upon closing and provides immediate capital for clinical trial advancement. The securities are issued as restricted securities without registration rights.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance the THIO-101 Phase II clinical trial. The closing of the private placement is expected on October 15, 2025, subject to customary closing conditions. The filing notes that the securities were sold in reliance on exemptions from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933. No specific forward-looking guidance regarding future financial performance or clinical outcomes is provided in this document.
Key Facts for Investor Verification
- Verify the closing date of the private placement (expected October 15, 2025) and the actual net proceeds received after deducting offering expenses.
- Confirm the dilution impact of the 603,769 new shares and the potential future dilution from the 603,769 warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Investor Warrant (Exhibit 4.1) for specific covenants or adjustment provisions.
- Check subsequent filings for updates on the commencement of the THIO-101 Phase II trial Step 1, Part C.